Executive Director, Global Clinical Development, Early Hematology and Cell Therapy

Bristol Myers Squibb•Princeton, NJ

20h

About The Position

Working at Bristol Myers Squibb offers a challenging, meaningful, and life-changing experience, with unique work that transforms patient lives and employee careers. The company fosters growth and thriving alongside high-achieving teams, emphasizing balance and flexibility through competitive benefits. The Executive Director role is situated within Clinical Development, a global organization focused on the effective design and execution of drug development, driving clinical strategy, design, execution, and interpretation of clinical trials. This Executive Director will define the clinical development strategy for assets or indications within Early Clinical Development, specifically targeting malignant hematology indications such as lymphoma, multiple myeloma, and acute myeloid leukemia. The position involves direct supervision of multiple Clinical Trial Physicians and Clinical Scientists, offering career development opportunities. It encompasses strategy work across various malignant hematology indications and is crucial for collaborating with Research and Late Clinical Development teams to support ID1, ID2, and ID3 transitions and achieve Proof of Concept (PoC), providing insights into biology, translational elements, and overall benefit-risk assessments. The role oversees the development of differentiated and strategic Clinical Development Plans (CDPs) for multiple early assets, supporting programs from pre-IND through PoC. Additionally, it supports portfolio-wide activities like the Protocol Review Committee, extensive Business Development, and Quality and Compliance leadership. The Executive Director reports directly to the Vice President, Early Hematology and Cell Therapy, and is a core member of the early clinical development leadership team.

Requirements

MD
Greater than 10 years of extensive clinical trial, drug development, and regulatory experience
Strong scientific background
Understand early-stage drug development
Extensive experience designing and conducting Phase I and II clinical trials
Demonstrable success navigating health authority interactions
Proven track record in managing complex clinical programs
Deep understanding of biology, targets and translational science
Extensive experience of work with health authorities
Proven differentiated ability to support and manage across the totality of the early drug development spectrum
Ability to execute the BMS R&D People Strategy, and lead and develop a matrix team
Highly effective leader capable of working with Commercial, Medical, and all research functions of the company from Research through Regulatory
Comfortable with cross-functional drug and product development teams and managing in a matrix environment
Skilled at interacting externally, and at speaking engagements
Skilled at attracting, developing, and retaining skilled professionals

Nice To Haves

PhD or other high level degree
Management experience
Global experiences
Experience interacting with business development, particularly helping to evaluate the technical and franchise aspects for potential opportunities that shape the hematology clinical development strategy

Responsibilities

Set the clinical development strategy for assets or indications within Early Clinical Development with a focus on malignancy hematology indications
Directly supervise the work of multiple Clinical Trial Physicians and Clinical Scientists providing career development opportunities for individuals across a wide variety of backgrounds and experience levels
Include above disease / indication strategy work focusing on malignant hematology indications including but not limited to lymphoma, multiple myeloma, acute myeloid leukemia and others
Work with teams in Research and Late Clinical Development to support ID1, ID2 and ID3 transitions and achievement of Proof of Concept (PoC), providing insights into biology, translational elements as well as overall benefit risk assessments
Supervise the development of differentiated and strategic Clinical Development Plans (CDPs) for multiple early assets and support a broad program of work from pre-IND through to PoC
Support of across portfolio activities in line with Clinical Excellence, including e.g. Protocol Review Committee, extensive Business Development activities and Quality and Compliance leadership
Report directly to the Vice President, Early Hematology and Cell Therapy, and will deputize as required
Be a core member of the early clinical development leadership team
Create and communicate a vision for designing, conducting and executing innovative clinical development plans
Supervise the development, monitoring, analysis and interpretation of clinical trials
Supervise and have accountability for the clinical components of regulatory interactions
Help drive overall strategy for malignant hematology while ensuring a franchise overall portfolio view
Provide strategic insights into the clinical development plans
Lead clinical input for search and evaluation activities in business development and diligence efforts
Chair departmental Staff Meetings, PRC and represent governance meetings on an ad hoc basis
Build a franchise reputation that attracts innovators to bring their ideas to BMS
Create a Clinical Development strategy to develop programs from research into First-In-Human testing and up to the achievement of Proof of Concept
Lead and develop a group of Clinical Development professionals whose therapeutic area focus is in a malignant hematology
Ensure scientific and technical excellence of clinical development programs and deliverables
Recruit, develop and retain strong talent
Mentoring of talent/staff
Establish an effective and ethical culture that encourages teamwork, peer review, promotes cooperation and provides a supportive culture
Be responsible for developing a culture that values diversity of thought, supports coaching, fosters accountability and integrity, and supports process excellence and continuous improvement
Be responsible for oversight of select team budget and headcount
Work closely with colleagues in BMS Research, Development, Regulatory, Medical, Commercial and other key functional areas on a global basis
Build relationships with thought leaders, physicians, and patient advocacy groups outside of BMS
Partner and interact with colleagues from Research and Late Development and will assure a seamless transition into late stage development (Phase II-III trials.)
Governance participation ad hoc as designated
PRC Chair ad hoc as needed
Signature Authority for: CSRs
Signature Authority for: Health Authority Interactions
Signature Authority for: DMC Charters
Signature Authority for: And other clinical accountable documents delegated as needed

Benefits

Competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives
Health Coverage: Medical, pharmacy, dental, and vision care
Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP)
Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support
Paid Time Off US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays
Unlimited paid sick time (Based on eligibility)
Up to 2 paid volunteer days per year (Based on eligibility)
Summer hours flexibility (Based on eligibility)
Leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs
Annual Global Shutdown between Christmas and New Years Day (All global employees full and part-time who are actively employed at and paid directly by BMS at the end of the calendar year are eligible to take advantage of the Global Shutdown)